Piscatelli Joseph A, Ban Jisun, Lucas Andrew T, Zamboni William C
UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA.
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Pharmaceutics. 2021 Jan 17;13(1):114. doi: 10.3390/pharmaceutics13010114.
Major developments in nanomedicines, such as nanoparticles (NPs), nanosomes, and conjugates, have revolutionized drug delivery capabilities over the past four decades. Although nanocarrier agents provide numerous advantages (e.g., greater solubility and duration of systemic exposure) compared to their small-molecule counterparts, there is considerable inter-patient variability seen in the systemic disposition, tumor delivery and overall pharmacological effects (i.e., anti-tumor efficacy and unwanted toxicity) of NP agents. This review aims to provide a summary of fundamental factors that affect the disposition of NPs in the treatment of cancer and why they should be evaluated during preclinical and clinical development. Furthermore, this chapter will highlight some of the translational challenges associated with elements of NPs and how these issues can only be addressed by detailed and novel pharmacology studies.
在过去的四十年里,纳米药物领域取得了重大进展,如纳米颗粒(NPs)、纳米体和缀合物,彻底改变了药物递送能力。尽管与小分子药物相比,纳米载体药物具有许多优势(例如,更高的溶解度和更长的全身暴露时间),但在纳米颗粒药物的全身分布、肿瘤递送和整体药理作用(即抗肿瘤疗效和不良毒性)方面,患者之间存在相当大的差异。本综述旨在总结影响纳米颗粒在癌症治疗中分布的基本因素,以及为何在临床前和临床开发过程中应对这些因素进行评估。此外,本章将重点介绍与纳米颗粒相关要素有关的一些转化挑战,以及如何只有通过详细的新型药理学研究才能解决这些问题。